Tuesday 1 March 2011

Annual Evidence Updates for March

NHS Evidence Specialist Collections produce Annual Evidence Updates (AEUs), which highlight good quality evidence from a search of research evidence on a particular topic over a 12 month period. They may also include user-friendly summaries written by relevant experts and links to guidelines, secondary research and primary research. NHS Evidence does the literature search so you don't have to!

7 March

Prostate cancer

The following commentaries will be available:
  • The benefits of robotic surgery over open surgery
  • Optimizing the use of prostate biopsy
  • Biological therapy
  • Patient information
  • Complementary therapies and prostate cancer
  • Ethnicity and prostate cancer
14 March

Hearing disorders

A concise summary of the latest guidance and systematic reviews, combined with a list of current therapeutic uncertainties to prioritise future research.

Critical Illness Rehabilitation

This AEU will cover the physical and non-physical consequences of critical illness including muscle weakness, anxiety and cognitive impairment

Retinal vein occlusions

This update will be restricted to systematic reviews and randomised controlled trials (RCTs). The RCTs of note concerning the treatment of macular oedema in retinal vein occlusion are the SCORE, CRUISE, BRAVO and OZURDEX studies.

21st March

Inflammatory Bowel Disease

This AEU will present the results of the Gastroenterology and Liver Diseases Project Team’s systematic search to update the results of the 2010 update.

Chest pain of recent onset

Assessment and investigation of recent onset chest pain, and discomfort of suspected cardiac origin . Critical appraisal of new systematic reviews and randomised trials covering the spectrum from assessment to early management of this condition.

28th March

Multiple Sclerosis

Guidelines, systematic reviews, health technology assessments and economic evaluations. Leading MS experts from around the UK have read and appraised these for their validity and relevance.

No comments: